会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Synthesis of intermediates for the preparation of pramipexol
    • 用于制备普拉克索的中间体的合成
    • US07662610B2
    • 2010-02-16
    • US11622259
    • 2007-01-11
    • Sergio RivaPaola FassiMichele ScarpelliniPietro AllegriniGabriele Razzetti
    • Sergio RivaPaola FassiMichele ScarpelliniPietro AllegriniGabriele Razzetti
    • C12P41/00
    • C12P17/14C07D277/82C12P41/005
    • A process for the preparation of an acid of formula (I), as the individual (R) enantiomer or (S), or a salt thereof wherein R is a protected amino group; and the asterisk * denotes the stereogenic carbon atom, comprising contacting an ester of formula (II), as mixture of (R,S) enantiomers, or a salt thereof, wherein R1 is straight or branched C1-C6 alkyl, optionally substituted with phenyl; (the asterisk * and R defined above), with a lipase from Candida antarctica, under conditions effective to obtain a mixture comprising an acid of formula (I), as the individual (R) enantiomer, and an ester of formula (II), as the individual (S) enantiomer; the subsequent hydrolysis of the latter to obtain an acid of formula (I), as the individual (S) enantiomer; and, if desired, the conversion of an acid of formula (I), either as the (R) or (S) enantiomer, to a salt thereof.
    • 制备式(I)的酸作为单个(R)对映异构体或(S)的方法或其盐,其中R是被保护的氨基; 并且星号*表示立体碳原子,包括使式(II)的酯作为(R,S)对映体或其盐的混合物接触,其中R 1是直链或支链的C 1 -C 6烷基,任选被苯基 ; (上文定义的星号*和R)与来自南极念珠菌的脂肪酶在有效获得包含式(I)的酸的混合物作为个体(R)对映异构体的条件下,和式(II)的酯, 作为个体(S)对映体; 随后水解后者以获得式(I)的酸作为单独的(S)对映异构体; 如果需要,将式(I)的酸作为(R)或(S)对映异构体转化为其盐。
    • 2. 发明申请
    • SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF PRAMIPEXOL
    • 合成制备PRAMIPEXOL的中间体
    • US20070166814A1
    • 2007-07-19
    • US11622259
    • 2007-01-11
    • Sergio RIVAPaola FassiMichele ScarpelliniPietro AllegriniGabriele Razzetti
    • Sergio RIVAPaola FassiMichele ScarpelliniPietro AllegriniGabriele Razzetti
    • C12P41/00
    • C12P17/14C07D277/82C12P41/005
    • A process for the preparation of an acid of formula (I), as the individual (R) enantiomer or (S), or a salt thereof wherein R is a protected amino group; and the asterisk * denotes the stereogenic carbon atom, comprising contacting an ester of formula (II), as mixture of (R, S) enantiomers, or a salt thereof, wherein R1 is straight or branched C1-C6 alkyl, optionally substituted with phenyl; the asterisk * and R defined above), with a lipase from Candida antarctica, under conditions effective to obtain a mixture comprising an acid of formula (I), as the individual (R) enantiomer, and an ester of formula (II), as the individual (S) enantiomer; the subsequent hydrolysis of the latter to obtain an acid of formula (I), as the individual (S) enantiomer; and, if desired, the conversion of an acid of formula (I), either as the (R) or (S) enantiomer, to a salt thereof.
    • 制备式(I)的酸作为单个(R)对映异构体或(S)的方法或其盐,其中R是被保护的氨基; 并且星号*表示立体碳原子,包括使式(II)的酯作为(R,S)对映体或其盐的混合物,其中R 1是直链或支链C 任选被苯基取代的C 1 -C 6烷基; 在有效获得包含式(I)的酸的混合物作为单独的(R)对映异构体和式(II)的酯的混合物的条件下,将来自南极念珠菌的脂肪酶与式(II)的酯作为 个体(S)对映体; 随后水解后者以获得式(I)的酸作为单独的(S)对映异构体; 如果需要,将式(I)的酸作为(R)或(S)对映异构体转化为其盐。
    • 9. 发明授权
    • Process for the preparation of pyridine compounds
    • 吡啶化合物的制备方法
    • US07605268B2
    • 2009-10-20
    • US11737852
    • 2007-04-20
    • Pietro AllegriniMarcello RaspariniGabriele RazzettiRoberto RossiGianpiero Ventimigla
    • Pietro AllegriniMarcello RaspariniGabriele RazzettiRoberto RossiGianpiero Ventimigla
    • C07D401/12
    • C07D471/04C07D401/12
    • A process for preparation of a compound of formula (I), both as the isomeric mixture and individual isomers, wherein Q is ═CR8— or ═N—; each R1, R2, R3, R4 is independently selected from hydrogen, halogen, hydroxy; nitro; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen or C1-C6 alkoxy; phenyl-C1-C6 alkyl; phenyl-C1-C6 alkoxy; and —N(RaRb) wherein each Ra and Rb is independently hydrogen or C1-C6 alkyl or Ra and Rb, taken together with the nitrogen atom they are linked to, form a saturated heterocyclic ring; and each R5, R6, R7, R8 is independently selected from hydrogen, halogen, hydroxy; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen; C1-C6 alkyl-carbonyl, C1-C6 alkoxy-carbonyl, and oxazol-2-yl; comprising converting a compound of formula (IV), to said compound of formula (I), in the presence of a catalyst, if necessary in an organic solvent.
    • 制备式(I)化合物的方法,均为异构体混合物和各异构体,其中Q为-CR8-或-N-; 每个R 1,R 2,R 3,R 4独立地选自氢,卤素,羟基; 硝基 任选被羟基取代的C 1 -C 6烷基; 烷硫基C1-C6; 任选被卤素或C 1 -C 6烷氧基取代的C 1 -C 6烷氧基; 苯基-C 1 -C 6烷基; 苯基-C 1 -C 6烷氧基; 和-N(RaRb),其中每个R a和R b独立地是氢或C 1 -C 6烷基或R a和R b与它们连接的氮原子一起形成饱和杂环; 并且每个R 5,R 6,R 7,R 8独立地选自氢,卤素,羟基; 任选被羟基取代的C 1 -C 6烷基; 烷硫基C1-C6; 任选被卤素取代的C 1 -C 6烷氧基; C 1 -C 6烷基 - 羰基,C 1 -C 6烷氧羰基和恶唑-2-基; 包括在催化剂存在下,如果需要在有机溶剂中将式(Ⅳ)化合物转化为所述式(Ⅳ)化合物。